BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 27, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2016

View Archived Issues

FDA grants orphan drug status to BioVie's BIV-201 for ascites

Read More

Bristol-Myers Squibb initiates phase I/II trial of BMS-986183 in advanced hepatocellular carcinoma

Read More

GSK initiates phase II trial of GSK-2982772 in psoriasis

Read More

Oncology Venture incorporates oncology therapeutics spin-out 2X Oncology in U.S.

Read More

AdAlta signs manufacturing agreement for AD-114

Read More

FDA clears IND for phase I trial of Cantrixil in ovarian cancer

Read More

RespireRx announces preliminary topline data from phase IIa trial of CX-1739

Read More

Horizon Pharma to acquire Raptor Pharmaceutical

Read More

GlaxoSmithKline submits MAA for sirukumab in rheumatoid arthritis

Read More

Novel RBM20 gene mutation linked to left ventricular noncompaction cardiomyopathy

Read More

FDA gives fast track designation to niraparib, Tesaro begins rolling NDA submission

Read More

SK Biopharmaceuticals patents mGlu5 receptor PAMs

Read More

First patient dosed in Xencor's phase I study of Xmab-14045

Read More

Sunshine Lake Pharma and Calitor Sciences disclose PI3Kdelta inhibitors

Read More

Bayer Pharma describes anticancer agents

Read More

Bristol-Myers Squibb reports development of NS5B inhibitors

Read More

Amplyx Pharmaceuticals doses first patients in phase I study of antifungal agent

Read More

Janssen-Cilag submits MAA to EMA for darunavir-based single tablet regimen

Read More

MacroGenics regains rights to MGD-010 from Takeda

Read More

VCAM1 and ANGPTL4 show promise as successful pleurodesis biomarkers

Read More

Repros Therapeutics submits MAA for enclomiphene

Read More

Mutations in PRODH2 could be genetic cause of hydroxyprolinemia

Read More

PNPLA4 identified as novel causative gene for mitochondrial respiratory chain disorders

Read More

Janssen applies for emergency use assessment and listing of Ebola prime-boost vaccine regimen

Read More

FDA clears Angionetics' phase III study of Generx gene therapy

Read More

UD-009 shows efficacy in pulmonary fibrosis model

Read More

Interim topline data from phase Ib study of GED-0301 in active Crohn's disease

Read More

Brain penetration, effects on disease seen with SBC-103 in mucopolysaccharidosis IIIB

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing